Bone Biologics Corporation
BBLG
$1.16
-$0.05-4.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -9.78% | -5.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.49% | -4.38% | |||
| Operating Income | -2.49% | 4.38% | |||
| Income Before Tax | -2.68% | 9.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.68% | 9.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.68% | 9.97% | |||
| EBIT | -2.49% | 4.38% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -2.29% | 72.02% | |||
| Normalized Basic EPS | -2.28% | 72.03% | |||
| EPS Diluted | -2.29% | 72.02% | |||
| Normalized Diluted EPS | -2.28% | 72.03% | |||
| Average Basic Shares Outstanding | 0.39% | 221.82% | |||
| Average Diluted Shares Outstanding | 0.39% | 221.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||